Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools IDH-mutant glioma

IDH-mutant glioma

Programs, trials, and reported response and survival for IDH-mutant glioma.

Data as of 11.07.2026

Standard of care

Standard of care

IDH mutant glioma is not one diagnosis. Treatment depends on astrocytoma versus oligodendroglioma, integrated molecular grade, residual disease, and whether radiotherapy and chemotherapy can safely be deferred. Vorasidenib is an approved postoperative grade 2 option in the setting the review describes. It is not a proven substitute for chemoradiation in aggressive or higher grade disease.

NOT INVESTMENT ADVICE. This is a general evidence review, not individualized medical advice. A line is shown only when the cited review or a trial record in this file states it.

No drugs selected. The grid shows every stated option.

How to read a tile

  • Filled tile. Approved for that lane.
  • Outlined tile. Guideline or off label. Local, Exception, and Not established use the same outline with those words.
  • Dashed tile. Investigational, with the phase and any stated FDA date. Pending review is not approval.

An empty cell reads “No standard.” The words on the tile carry the status. Border style repeats it.

SubgroupSurgeryWhen radiotherapy and chemotherapy can be deferredDefinitive treatmentMaintenance after treatmentRecurrence
Grade 2 oligodendrogliomaThe review separates oligodendroglioma from astrocytoma, and grade 2 deferral from definitive treatment.

No standard

Grade 2 IDH-mutant astrocytomaVorasidenib is an approved postoperative grade 2 option. It is not a proven substitute for chemoradiation.

No standard

Grade 3 oligodendrogliomaThe review names radiotherapy plus PCV as the best established regimen for 1p/19q codeleted grade 3 disease.

No standard

No standard

Grade 3 IDH-mutant astrocytomaCATNON supports radiotherapy followed by adjuvant temozolomide for non codeleted disease.

No standard

No standard

Grade 4 IDH-mutant astrocytomaThe review says this is not IDH wildtype glioblastoma, and vorasidenib is not approved for grade 4.

No standard

No standard

Maintenance record, grade not statedVIGOR names IDH mutant astrocytoma after treatment. SIGMA names maintenance after standard therapy. Neither placement states a grade.

No standard

No standard

No standard

No standard

Surgery

Grade 2 oligodendroglioma

The review separates oligodendroglioma from astrocytoma, and grade 2 deferral from definitive treatment.

Grade 2 IDH-mutant astrocytoma

Vorasidenib is an approved postoperative grade 2 option. It is not a proven substitute for chemoradiation.

Grade 3 oligodendroglioma

The review names radiotherapy plus PCV as the best established regimen for 1p/19q codeleted grade 3 disease.

Grade 3 IDH-mutant astrocytoma

CATNON supports radiotherapy followed by adjuvant temozolomide for non codeleted disease.

Grade 4 IDH-mutant astrocytoma

The review says this is not IDH wildtype glioblastoma, and vorasidenib is not approved for grade 4.

Maintenance record, grade not stated

VIGOR names IDH mutant astrocytoma after treatment. SIGMA names maintenance after standard therapy. Neither placement states a grade.

No standard

When radiotherapy and chemotherapy can be deferred

Grade 3 oligodendroglioma

The review names radiotherapy plus PCV as the best established regimen for 1p/19q codeleted grade 3 disease.

No standard

Grade 3 IDH-mutant astrocytoma

CATNON supports radiotherapy followed by adjuvant temozolomide for non codeleted disease.

No standard

Grade 4 IDH-mutant astrocytoma

The review says this is not IDH wildtype glioblastoma, and vorasidenib is not approved for grade 4.

No standard

Maintenance record, grade not stated

VIGOR names IDH mutant astrocytoma after treatment. SIGMA names maintenance after standard therapy. Neither placement states a grade.

No standard

Definitive treatment

Grade 2 oligodendroglioma

The review separates oligodendroglioma from astrocytoma, and grade 2 deferral from definitive treatment.

Maintenance record, grade not stated

VIGOR names IDH mutant astrocytoma after treatment. SIGMA names maintenance after standard therapy. Neither placement states a grade.

No standard

Maintenance after treatment

Grade 2 oligodendroglioma

The review separates oligodendroglioma from astrocytoma, and grade 2 deferral from definitive treatment.

No standard

Grade 2 IDH-mutant astrocytoma

Vorasidenib is an approved postoperative grade 2 option. It is not a proven substitute for chemoradiation.

No standard

Grade 3 oligodendroglioma

The review names radiotherapy plus PCV as the best established regimen for 1p/19q codeleted grade 3 disease.

No standard

Grade 3 IDH-mutant astrocytoma

CATNON supports radiotherapy followed by adjuvant temozolomide for non codeleted disease.

No standard

Grade 4 IDH-mutant astrocytoma

The review says this is not IDH wildtype glioblastoma, and vorasidenib is not approved for grade 4.

No standard

Recurrence

Maintenance record, grade not stated

VIGOR names IDH mutant astrocytoma after treatment. SIGMA names maintenance after standard therapy. Neither placement states a grade.

No standard

Sources

  • I1CAP molecular biomarker testing for diffuse gliomasCAP, AANP, AMP, and SNO diagnostic guideline.
  • I2ASCO SNO therapy for diffuse astrocytic and oligodendroglial tumors2021 guideline, published 2022.
  • I3ASCO SNO rapid recommendation update, 2025Conditional vorasidenib recommendation when radiotherapy and chemotherapy can be deferred.
  • I4VORANIGO U.S. prescribing informationRevised June 2026.
  • I5INDIGO, vorasidenib in IDH mutant low grade gliomaMellinghoff et al., NEJM 2023. Randomized phase III.
  • I6RTOG 9802, radiotherapy plus PCV for low grade gliomaBuckner et al., NEJM 2016. Historical high risk cohort.
  • I7Joint final report of EORTC 26951 and RTOG 9402Lassman et al., JCO 2022. Long term PCV evidence.
  • I8CATNON final and exploratory analysesvan den Bent et al., Lancet Oncology 2026.
  • I9ESTRO EANO radiotherapy guideline for IDH mutant grade 2 and 3 diffuse glioma2024 guideline.
  • I10Multidisciplinary recommendations for routine follow up of IDH mutant glioma in 2026Neuro-Oncology Practice 2026.
  • I11INDIGO extended follow up, ASCO 2026 abstractConference evidence. Post unblinding follow up is not a new randomized comparison.
  • I12INDIGO ASCO 2026 presentationCorrected investigator assessed median PFS 51.6 months. Blinded independent central review 44.1 months.
  • I13EANO guidelines on diffuse gliomas of adulthoodWeller et al., Nature Reviews Clinical Oncology 2021.
  • I14Australian expert position statement on IDH mutant glioma2026 multidisciplinary context, not a U.S. label.
  • I15TEMODAR U.S. prescribing informationTemozolomide monitoring and Pneumocystis prophylaxis.
  • NCT06809322VIGOR, ClinicalTrials.govSponsor entered record cited for maintenance vorasidenib in IDH mutant astrocytoma after treatment.
  • NCT07712757Safusidenib G307, ClinicalTrials.govSponsor entered record cited for surgery only grade 2 disease.
  • NCT05303519Safusidenib SIGMA, ClinicalTrials.govSponsor entered record cited for maintenance after standard therapy.
  • NCT07703436Safusidenib G209, ClinicalTrials.govSponsor entered record cited for grade 2 or 3 disease after vorasidenib progression.
  • NCT07832123SAFU-G3, ClinicalTrials.govSponsor entered record cited for newly diagnosed grade 3 astrocytoma or oligodendroglioma.
  • NCT07912398HMPL-306 phase 3, ClinicalTrials.govSponsor entered record cited for surgery only nonenhancing grade 2 disease. The seed population text is wider. The seed was not edited.
  • VOR-PH1Vorasidenib phase 1 in recurrent or progressive gliomaMellinghoff et al., Clinical Cancer Research 2021. Cited in the IDH seed.
  • IVO-PH1Ivosidenib in IDH1 mutated advanced gliomaMellinghoff et al., JCO 2020. Cited in the IDH seed.
  • OLU-PH12Olutasidenib in IDH1 mutant relapsed or refractory gliomade la Fuente et al., Neuro-Oncology 2023. Cited in the IDH seed.
  • OLAGLI-PMCOLAGLI, olaparib in recurrent IDH mutant high grade gliomaCited in the IDH seed.

All drugs